



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 13, 2020

Chris Hollowood  
Chairman  
Freeline Therapeutics Holdings Ltd  
Stevenage Bioscience Catalyst  
Gunnels Wood Road  
Stevenage, Hertfordshire SG1 2FX

**Re: Freeline Therapeutics Holdings Ltd**  
**Amendment No. 3 to Draft Registration Statement on Form F-1**  
**Submitted July 6, 2020**  
**File No. 377-03158**

Dear Dr. Hollowood:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 3 to Draft Registration Statement submitted July 6, 2020

Summary

Our Pipeline, page 4

1. We note that you have changed the arrow positioning in your pipeline chart for FLT180a to extend to the end of Phase 1/2 even though your disclosure states that the Phase 1/2 trial for FLT180a has not yet been completed and that the pivotal clinical trial for FLT180a will be a Phase 2b/3 trial. Please revert the arrow positioning here and on page 133 to reflect the status of the product candidate indicated by the disclosure.

Chris Hollowood  
Freeline Therapeutics Holdings Ltd  
July 13, 2020  
Page 2

Capitalization, page 106

2. Please revise and reflect your Series C Financing on a Pro Forma basis in the capitalization table.

You may contact Christie Wong at 202-551-3684 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Alan Campbell at 202-551-4224 or Celeste Murphy at 202-551-3257 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Marcel Fausten